Guilin Sanjin (002275) stated during an institutional survey on June 21 that currently, the sales revenue of first-line products such as Watermelon Frost series and Sanjin tablets series accounts for nearly 80% of total revenue. The company is currently developing its products for the second time, such as launching new dosage forms, increasing indications, and combination therapy. The sales of the company's products still have potential for growth in the corresponding markets of oral and throat, and urinary system. Currently, OTC accounts for a large proportion, and the next step is to expand sales in hospitals.